nl-chchd-001
Nucleic acidexperimental
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Apr 16, 2024 (NCT06392126)
Timeline
2020s
- Jan 1, 2024
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- UnclearANTISENSE INHIBITOR
Unclear antisense inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07095686 | Phase 1/Phase 2 (Phase 2) | Oct 2, 2024 | Columbia University, n-Lorem Foundation |
| NCT06977451 | Phase 1/Phase 2 (Phase 2) | Jun 24, 2024 | Columbia University, n-Lorem Foundation |
| NCT06392126 | Phase 1/Phase 2 (Phase 2) | Apr 16, 2024 | Mayo Clinic, n-Lorem Foundation |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| n-Lorem Foundation | Academic/Hospital | 3 | 3 | 1 | 2024 |
| Columbia University | Academic/Hospital | 2 | 0 | 1 | 2024 |
| Mayo Clinic | Academic/Hospital | 1 | 0 | 1 | 2024 |
3 organizations
Page 1 / 1